Embecta Corp. (EMBC) – What Are Analysts Thinking About This Stock?

Embecta Corp. (NASDAQ:EMBC) has earned an average rating of “Reduce” from the five research firms that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating and three have given a hold rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $11.00.

Several research analysts have commented on EMBC shares. Weiss Ratings upgraded shares of Embecta from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, October 9th. Zacks Research upgraded shares of Embecta from a “strong sell” rating to a “hold” rating in a research note on Friday, July 17th.

Embecta Stock Performance

Embecta stock opened at $6.18 on Thursday. Embecta has a one year low of $2.77 and a one year high of $14.91. The company has a 50-day simple moving average of $5.36 and a 200-day simple moving average of $5.05. The firm has a market capitalization of $350.16 million, a P/E ratio of 4.18 and a beta of 0.84.

Embecta (NASDAQ:EMBC) last released its quarterly earnings data on Friday, August 7th. The company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.29. The business had revenue of $271.70 million for the quarter, compared to analysts’ expectations of $254.53 million. Embecta had a net margin of 8.59% and a negative return on equity of 19.25%. The company’s revenue for the quarter was down 8.1% compared to the same quarter last year. During the same quarter last year, the company earned $1.12 EPS. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. As a group, sell-side analysts forecast that Embecta will post 1.84 earnings per share for the current year.

Embecta Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 15th. Stockholders of record on Thursday, August 27th were given a dividend of $0.01 per share. The ex-dividend date was Thursday, August 27th. This represents a $0.04 annualized dividend and a dividend yield of 0.6%. Embecta’s payout ratio is currently 2.70%.

Insiders Place Their Bets

In related news, Director Milton Mayo Morris sold 6,293 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $5.88, for a total value of $37,002.84. Following the sale, the director directly owned 53,828 shares in the company, valued at $316,508.64. This trade represents a 10.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Devdatt Kurdikar purchased 30,000 shares of Embecta stock in a transaction on Wednesday, August 12th. The shares were acquired at an average price of $4.70 per share, with a total value of $141,000.00. Following the transaction, the chief executive officer directly owned 804,919 shares in the company, valued at $3,783,119.30. This trade represents a 3.87% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders acquired 70,000 shares of company stock valued at $334,200. 1.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. One Wealth Advisors LLC acquired a new position in shares of Embecta during the second quarter valued at $33,000. GAMMA Investing LLC lifted its holdings in Embecta by 101.5% in the third quarter. GAMMA Investing LLC now owns 10,898 shares of the company’s stock worth $62,000 after purchasing an additional 5,490 shares during the period. Public Employees Retirement System of Ohio acquired a new stake in Embecta in the second quarter worth about $133,000. Sei Investments Co. acquired a new stake in Embecta in the first quarter worth about $138,000. Finally, Alpine Global Management LLC acquired a new stake in Embecta in the fourth quarter worth about $178,000. 93.83% of the stock is owned by institutional investors and hedge funds.

Embecta Company Profile

Embecta Corporation (NASDAQ: EMBC) is a global diabetes-care company that develops, manufactures and markets medical devices used to deliver insulin and monitor blood glucose. Its product portfolio includes insulin pen needles, insulin syringes, safety-engineered injection devices, lancets and related diabetes-management products.

The company serves people with diabetes, health care professionals, hospitals and other health care providers through commercial operations and distribution partners in markets around the world.